Compare BTT & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTT | FTRE |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | BTT | FTRE |
|---|---|---|
| Price | $22.79 | $16.75 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $12.64 |
| AVG Volume (30 Days) | 151.1K | ★ 1.4M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 2.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,759,900,000.00 |
| Revenue This Year | N/A | $3.17 |
| Revenue Next Year | N/A | $0.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.88 |
| 52 Week Low | $18.90 | $3.97 |
| 52 Week High | $21.86 | $20.26 |
| Indicator | BTT | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 63.50 | 63.79 |
| Support Level | $22.24 | $17.06 |
| Resistance Level | $22.54 | $17.69 |
| Average True Range (ATR) | 0.17 | 0.81 |
| MACD | 0.04 | -0.14 |
| Stochastic Oscillator | 83.87 | 49.13 |
Blackrock Municipal 2030 Target Term Trust is a United States-based closed-end management investment company. The investment objective of the company is to provide current income exempt from regular federal income tax and to return $25.00 per common share to holders of common shares. The trust seeks to achieve its investment objectives by investing a majority of its assets in municipal bonds exempt from U.S. federal income taxes.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.